We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Medtech Insight is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Ophthalmic device and drug developer Avedro Inc. has raised $43mm through its Series D venture round led by Abingworth. Third Point also made a significant investment, and was joined by existing shareholders Prism Venture Works, De Novo Ventures, Flagship Ventures, Aperture Ventures, SCP Vitalife Venture Partners, Borealis Ventures, and Echelon Ventures. Abingworth and Third Point will gain representation on Avedro’s board. The company will use the proceeds for R&D activities involving corneal crosslinking (for cataract and refractive surgery), to gain US approval for future products, and for global commercialization.
Deal Industry
Medical Devices
Pharmaceuticals
Medical Devices
Diagnostic Equipment & Supplies
Laser
Surgical Equipment & Devices
Minimally or Less Invasive
Deal Status
Final
Deal Type
Financing
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?